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ABSTRACT
DNA double-strand breaks (DSBs) can be generated
not only by reactive agents but also as a result of
replication fork collapse at unrepaired DNA
lesions. Whereas ubiquitylation of proliferating cell
nuclear antigen (PCNA) facilitates damage bypass,
modification of yeast PCNA by small ubiquitin-like
modifier (SUMO) controls recombination by pro-
viding access for the Srs2 helicase to disrupt
Rad51 nucleoprotein filaments. However, in human
cells, the roles of PCNA SUMOylation have not been
explored. Here, we characterize the modification of
human PCNA by SUMO in vivo as well as in vitro. We
establish that human PCNA can be SUMOylated at
multiple sites including its highly conserved K164
residue and that SUMO modification is facilitated
by replication factor C (RFC). We also show that ex-
pression of SUMOylation site PCNA mutants leads
to increased DSB formation in the Rad18/ cell line
where the effect of Rad18-dependent K164 PCNA
ubiquitylation can be ruled out. Moreover, expres-
sion of PCNA-SUMO1 fusion prevents DSB forma-
tion as well as inhibits recombination if replication
stalls at DNA lesions. These findings suggest the
importance of SUMO modification of human PCNA
in preventing replication fork collapse to DSB and
providing genome stability.
INTRODUCTION
Cellular DNA is continually damaged by a plethora of ex-
trinsic and intrinsic sources and repaired by a variety of
repair processes (1). However, DNA damages can also
escape repair and block the replication machinery of
which prolonged stalling can result in the collapse of
replication fork into DNA double-strand breaks (DSBs)
(2–4). Rescue of cells from replication collapse is important
since DSB formation can lead to deleterious chromosomal
rearrangements and cancer. To sustain the continuity of
replication, other defence systems, the so-called DNA
damage tolerance pathways are activated which do not
repair DNA damage, but their action results in the comple-
tion of replication of damaged DNA (5,6). The Rad6–
Rad18 ubiquitin-conjugating complex-dependent defence
system governs translesion synthesis by specialized DNA
polymerases as well as a template switch-dependent
post-replicative repair pathway (7–10) Homologous
recombination-dependent mechanisms can also rescue the
stalled replication fork providing, thereby, alternative
means for DNA damage tolerance (2,11–13)
Although replication through damaged DNA as well as
homologous recombination can be error-free, unregulated
damage bypass and recombination can lead to genome
instability (7,14). To minimize the danger, these DNA
damage tolerance pathways are thought to be kept
under tight control such as by various post-translational
modifications of proliferating cell nuclear antigen
(PCNA), the processivity factor of replication, which
serves also as a platform for giving access for repair
players to DNA (15–17). Yeast genetic studies have been
instrumental in providing evidence that PCNA mon-
oubiquitylation is required for translesion synthesis,
PCNA K63-linked polyubiquitylation governs template
switch-dependent replication through DNA lesions,
whereas modification of PCNA by small ubiquitin-like
modifier (SUMO) prevents recombination and also regu-
lates template switch (12,18–22). It has been suggested
that PCNA–SUMO can provide access for the yeast
Srs2 helicase to disrupt Rad51 nucleoprotein filaments
thereby keeping recombination under control (12,14,23).
These studies suggest that reviving replication forks by
recombination could be disadvantageous for cells,
probably because it can lead to gross chromosomal re-
arrangements. PCNA–SUMO functions as a guardian
during replication of damaged DNA by preventing recom-
bination and facilitating the use of the Rad6–Rad18-de-
pendent damage tolerance pathway (17,24). However, the
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structure of the DNA substrates that arise from the stalled
replication fork in the absence of PCNA–SUMO, the
mechanism of recombination and the exact role of
PCNA–SUMO at the stalled replication fork have
remained elusive.
In mammalian cells, the significance of mono- and
poly-ubiquitylation of PCNA has been demonstrated.
Although PCNA SUMOylation has been reported in
higher eucaryotes such as in Xenopus and chicken cells
(25,26), the SUMO-dependent regulation of recombin-
ation has been assumed to be important only in particular
eukaryotic cells with a naturally high rate of recombin-
ation such as yeast (20). Very recently, SUMOylation of
human PCNA has also been found and shown that it
preferentially interacts with a PCNA interacting protein
(PARI) (27). PARI has been suggested to suppress
inappropriate recombination events at the replication
fork; however, the direct role of SUMO modification of
human PCNA has not been studied.
Here, we characterize the modification of human PCNA
by SUMO. Notably, we suggest that the presence of the
SUMO moiety on human PCNA can prevent DSB forma-
tion as well as inappropriate recombination if replication
stalls at DNA lesions. We discuss the possibility that in the
absence of PCNA-SUMO stalled replication forks
collapse more frequently to DSBs, which then become
substrates for DSB repair-associated recombination-de-
pendent DNA damage tolerance mechanism.
MATERIALS AND METHODS
Detailed information about materials and methods not
provided here can be found in the Supplementary
information.
Proteins, cell culture and antibodies
Plasmids for protein expressions in human cells and for
protein purifications in yeasts and in Escherichia coli,
purified proteins (PCNA and lysine to arginine mutants
of PCNA, SUMO1, SUMO2, SUMO3, Pias1, Pias2,
Pias3, Pias4, hUBC9, SAE1/SAE2, PCNA-SUMO1
fusion and RFC) and cell cultures used for in vivo/in vitro
human PCNA SUMOylation studies are explained in the
Supplementary Data. For immunostainings an anti-FLAG
mAb 1:400 M2 (Sigma F3165), anti-FLAG 1:400 (Sigma
F7425), anti-BrdU 1:500 (Ab-direct Serotech), anti-
gH2Ax 1:5000 (Upstate 05-636), anti-mouse Cy3 1:1000
(Sigma C2181), AlexaFluor 488-labelled goat anti-rat
antibody 1:1000 (Molecular Probes, Inc.) and anti-rabbit
FITC 1:1000 (Sigma F0382) antibodies were used.
In vitro assays for PCNA SUMOylation and
polymerase stimulation
In vitro SUMOylation reaction of PCNA contained 40 nM
PCNA, 10 nM SAE1/2, 100 nM Ubc9, 500 nM SUMO1,
10 nM RFC and 2 nM nicked PUC19 plasmid DNA.
Reactions were incubated at 37C for 60min and the prod-
ucts were separated on 10% denaturing polyacrylamide
gel and visualized by western blot using anti-PCNA
antibody (Santa Cruz PC10).
For DNA polymerase stimulation assay (Figure 3B)
PolZ, Polk or Poli (2 nM each) was incubated with a
75/27-nt partial heteroduplex oligonucleotide DNA sub-
strate (10 nM) containing biotin–streptavidine at both
ends in the presence of RFC (5 nM), and either PCNA
(10 nM) or PCNA-SUMO1 fusion protein (10 nM) at
37C for 10min.
In vivo SUMOylation of PCNA and analysis of
recombination and cell survival
To detect SUMOylation of endogenous human PCNA
in vivo cells expressing hemagglutinin epitope tagged
(HA)-PCNA together with either FLAG epitope-tagged
(FLAG)-SUMO1, or FLAG-SUMO2, or FLAG-SUMO3
(Figure 1A and C) or stably expressing FLAG-SUMO1
(Figure 1B) were lysed and total cell extracts in a buffer
containing 50mM Tris–HCl (pH7.5), 200mM NaCl, 1%
NP-40, 0.1% SDS, 5mM EDTA, 10% glycerol and 1mM
PMSF were used for immunoprecipitation on FLAG
beads (Sigma) followed by immunoblot detection with
anti-HA (Roche 3F10) or anti-PCNA (Santa Cruz
PC-10) antibodies.
Frequency of I-SceI induced and spontaneous recombin-
ation were measured by a modified GFP-based reporter
system as described in the Supplementary Methods (28).
Cell survival was determined using Vialight Plus cell
proliferation/cytotoxicity Kit assay (Lonza) according to
the manufacturer’s instructions.
Monitoring DSB formation by detection of cH2AX foci
and neutral comet assay
For the detection of gH2AX foci cells stably expressing
FLAG, FLAG-SUMO1, FLAG-PCNA or FLAG
PCNA-SUMO1 were grown on coverslips and mock- or
MMS (0.01%)-treated for 1 h before immunostaining with
the anti-gH2AX antibody (Upstate 05-636) and analysis
by confocal laser scanning microscope.
For neutral comet assays (29), cells stably expressing
FLAG, FLAG-PCNA or FLAG-PCNA-SUMO1
were treated with 0.01% MMS or mock for 1 h. After
various time points, cells were embedded in agarose
blocks and analysed by non-denaturing electrophoresis
conducted at 4C for 20min at the electric field strength
of 25V and 15 mA as described in the Supplementary
Methods. The data were analysed for statistical signifi-
cance using the Student’s t-test. A value of P< 0.001
was considered to be statistically significant for compari-
son between data sets.
RESULTS
In vivo modification of human PCNA by SUMO
In our previous studies on polyubiquitin modification of
human PCNA, we occasionally detected higher mobility
PCNA shifts that raised the possibility that covalent
attachment of SUMO to human PCNA might occur
(30,31). To test directly for SUMOylation of human
PCNA, we transiently co-expressed HA-tagged PCNA
with FLAG-tagged SUMO1, SUMO2 or SUMO3 in
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human cells, and then performed FLAG immuno-
precipitations. Western blotting of the resulting samples
with anti-HA antibody established that PCNA was
indeed SUMOylated (Figure 1A). SUMOylation of
human PCNA was further confirmed by HA immuno-
precipitations of the samples from the same transfec-
tions and western blotting with anti-FLAG antibody
(Supplementary Figure S1). Notably, we detected two
higher mobility shifts suggesting at least two potential
SUMOylation sites in human PCNA, and although
SUMO1 predominantly conjugated to PCNA weak
attachment of SUMO2 and SUMO3 was also detectable.
Furthermore, the SUMOylation of PCNA did not require
exogenous DNA damage (Figure 1A). Next, we also
evaluated the endogenous PCNA SUMOylation in cells
stably expressing FLAG-SUMO1 by FLAG imm-
unoprecipitation followed by probing with anti-PCNA
antibody (Figure 1B). Also, we tested for the SUMO1
acceptor residues in human PCNA by mutating the
highly conserved lysine 164 residue the main SUMO
acceptor residue of yeast PCNA, to arginine, which
indeed eliminated one of the main SUMOylated PCNA
species (Figure 1C). Nevertheless, similar experiments
using all 16 single lysine mutant PCNAs did not help to
unambiguously define the other SUMO attachment sites
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Figure 1. In vivo SUMO modification of human PCNA. (A) HEK293T cells were co-transfected with HA-PCNA, His-UBC9 and either
FLAG-SUMO1, or FLAG-SUMO2, or FLAG-SUMO3. In 48 h, post-transfection cells were UV-treated (30 J/m2) or mock-irradiated and, after
3 h lysed and immunoprecipitated on FLAG-beads. FLAG-SUMO precipitates were immunoblotted with anti-HA antibody to detect PCNA and the
SUMO-modified forms of PCNA. The lower panel shows the anti-HA western blot of the lysates. (B) Cell lysates and FLAG immunoprecipitates
from control HeLa S3 cells and HeLa S3 cells stably expressing FLAG-SUMO1 were immunoblotted with anti-PCNA antibody to detect
SUMOylated forms of endogenous PCNA. (C) HEK293T cells were co-transfected with FLAG-SUMO1, His-UBC9 and either HA-PCNA or
K164R PCNA and 48-h post transfection cells were lysed and immunoprecipitated on FLAG-beads. FLAG-SUMO1 precipitates were
immunoblotted with anti-HA antibody to detect the effect of the K164R mutation on the SUMOylation of PCNA. (D) Interaction of PCNA
with UBC9 was tested by co-expressing FLAG-PCNA and HA-UBC9 in HEK293 cells followed by FLAG immunoprecipitation and then by western
blot analysis with anti-HA and anti-FLAG antibodies for UBC9 and PCNA, respectively.
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SUMOylation of its different acceptor lysine residues
can give rise to similar mobility PCNA shifts. In
line with PCNA SUMOylation, PCNA could be co-imm-
unoprecipitated with UBC9, the SUMO conjugating
enzyme (Figure 1D).
SUMOylation of human PCNA in a reconstituted
system using purified proteins
To further characterize, we set up an in vitro PCNA
SUMOylation system using purified E1 SUMO-activating
enzyme (SAE1/SAE2), E2 SUMO-conjugating enzyme
(Ubc9), various E3 SUMO-ligases (Pias1, Pias2, Pias3
and Pias4) and all three SUMO isoforms (SUMO1,
SUMO2 and SUMO3; Figure 2 and Supplementary
Figure S2). Consistently with the in vivo findings, we estab-
lished that out of the three SUMO isoforms, only SUMO1
could be efficiently conjugated to PCNA (Figure 2A) and
that the lysine 164 residue of PCNA was one of the main
SUMO attachment site (Figure 2D). In addition, using
surface lysine mutant PCNAs, we managed to identify
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Figure 2. In vitro SUMO modification of human PCNA. (A) in vitro SUMOylation reaction of human PCNA (40 nM) was carried out in the
presence of purified SAE1/2 (10 nM), Ubc9 (100 nM), RFC (10 nM) nicked PUC19 plasmid DNA (2 nM) and either GST-SUMO1, or GST-SUMO2,
or GST-SUMO3, or SUMO1, or SUMO2, or SUMO3 (500 nM) at 37C for 60min. Samples containing unmodified and SUMOylated PCNA were
separated on 10% denaturing polyacrylamide gel and visualized by western blot using anti-PCNA antibody. Structure of human PCNA from the
front (B) and side (C) views; surface lysine residues are represented by red spheres (K117, K138, K164, K168, K181, K190, K240, K248 and K254).
PCNA structures showing the surface lysine residues were generated using the PyMOL version 0.96 by DeLano scientific (http.//www
.pymolsourceforge.net). (D) Wild-type and lysine point-mutant PCNA samples were subjected to in vitro SUMOylation reaction as described
above. (E) In vitro SUMOylation and ubiquitylation reactions of PCNA were compared in the absence or presence of combinations of RFC and
nicked plasmid DNA as indicated.
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PCNA that locates in a consensus KxE SUMO attach-
ment site, where  is an aliphatic residue (Figures 2D).
Consistently with alternate lysine modifications that
we concluded from our in vivo experiments, at higher
enzyme concentrations, new SUMO-PCNA shifts
also became apparent, particularly for certain lysine
mutants (Supplementary Figure S2A). Strikingly, PCNA
SUMOylation was dependent on replication factor C
(Figure 2E), but did not require any of the four PIAS
E3 ligases (Supplementary Figure S2B). Moreover,
comparing PCNA SUMOylation with ubiquitylation in
the presence of RFC, nicked plasmid DNA or their com-
bination revealed that in contrast to ubiquitylation, which
requires RFC-dependent loading of PCNA onto DNA,
PCNA SUMOylation was dependent on RFC but not
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Figure 3. Effect of PCNA-SUMO1 fusion protein on translesion synthesis polymerases and qualitative analysis of PCNA-SUMO1 fusion protein.
(A) Schematic representation of the fusion of SUMO1 at the C-terminus of a FLAG-tagged PCNA and the control vectors expressing only FLAG,
FLAG-SUMO1 or FLAG-PCNA. (B) DNA polymerase reactions were carried out using various TLS DNA polymerases on DNA substrate
containing biotin–streptavidin at both ends generated by annealing a 75-nt long oligonucleotide template to a 50 labelled 27-nt primer DNA in
the presence of RFC and either PCNA or PCNA-SUMO1. The reaction products were analysed on 10% polyacrylamide gels containing 8M urea,
and the DNA bands were visualized by autoradiography. (C) HeLa cells stably expressing FLAG-PCNA and FLAG-PCNA-SUMO1 were pulse
labelled with 10 mM BrdU for 1 h and immunostained with antibodies against FLAG (red) and BrdU (green). (D) Stable cell lines expressing
FLAG-control, FLAG-PCNA and FLAG-PCNA-SUMO1 were subjected to flow cytometric analysis. Cell number is plotted on the y axis; DNA
content on the x axis. Black, G1 peak; grey, G2/M peak; white, S phase fraction.
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Thus, interaction between PCNA and RFC is a prerequis-
ite for PCNA SUMOylation presumably by exposing
residues in PCNA or giving access for Ubc9.
Characterization of PCNA-SUMO fusion protein
To directly investigate the role of SUMO modification of
human PCNA, we sought to generate a C-terminal fusion
of SUMO1 to PCNA resulting in a PCNA-SUMO1 con-
jugate, a known strategy (32–36) used to study the effect
of SUMOylation of target proteins (Figure 3A). Purified
PCNA and PCNA-SUMO1 chimera (Supplementary
Figure S3A) stimulated the DNA synthetic activity of
translesion polymerases Z, k and i equally well indicating
the proficiency of loading PCNA-SUMO1 by RFC and
suggesting that the SUMO-moiety on PCNA does not
affect the interaction between PCNA and translesion
synthesis polymerases (Figure 3B). Also, PCNA-SUMO1
was proficient in ubiquitylation reaction and localized
to replication foci similarly to PCNA, further corro-
borating the functionality of the PCNA-SUMO1
chimera (Supplementary Figure S3B and Figure 3C). In
addition, comparing flow cytometric profiles of stable cell
lines expressing PCNA or PCNA-SUMO1 confirmed that
PCNA-SUMO1 did not influence the cell cycle (Figure 3D
and Supplementary Figure S4B).
PCNA-SUMO1 fusion inhibits spontaneous as well as
DSB-induced homologous recombination
To measure the effect of the SUMO modification of
PCNA on the frequency of homologous recombination,
we employed a chromosomally integrated reporter
system, which measures the reconstituted expression of
green fluorescent protein (GFP) as events of homologous
recombination. Supporting the findings in yeast studies,
the expression of PCNA-SUMO1 conjugate in human
cells significantly lowered the rate of I-SceI-generated
DSB-induced homologous recombination (Figures 4A
and Supplementary Figure S4A), which indicated that
SUMO modification of human PCNA can control recom-
bination. Strikingly, the presence of PCNA-SUMO1 in
human cells had even stronger inhibitory effect on spon-
taneous recombination, which was almost completely
eliminated (Figure 4B) indicating that it might prevent
formation of DSBs. These experiments suggested that
PCNA-SUMO1 fusion could have two seemingly inde-
pendent functions in preventing recombination; on one
hand, it directly inhibits DSB-initiated homologous
recombination, and on the other hand, it could prevent
DSB formation, which indirectly inhibits recombination.
PCNA-SUMO1 reduces the accumulation of c-H2AX foci
To test for inhibition of DSB formation by PCNA-
SUMO1, we treated HeLa cells stably expressing
PCNA-SUMO1 with methyl methanesulphonate
(MMS), which does not generate DSBs directly, but
induces replication fork stalling, which can then be
converted into DSBs (3). The occurrence of MMS-
induced DSBs was measured by a sensitive indicator of
DNA DSBs in cells, histone H2AX phosphorylation
(g-H2AX). Notably, cells expressing PCNA-SUMO1
showed much fewer MMS-induced g-H2AX foci than
control cells as revealed by anti-g-H2AX immunostaining
(Figure 5A and B). Moreover, kinetic analysis of g-H2AX
foci formation and disappearance further confirmed this
finding and revealed no difference in the kinetics of DSB
repair indicating that the effect of PCNA-SUMO1 indeed
can stem from the inhibition of DSB formation (Figure 5C
and Supplementary Figure S4C). These data were further
confirmed in HCT116 and RAD18/ cell lines transiently
transfected with PCNA-SUMO1 and, in parallel, using
additional control transfections with SUMO1 and
PCNA-ubiquitin conjugate apart from PCNA alone and
control cell lines. We found PCNA-SUMO1 specific
inhibition of DSB formation in HCT116 cell lines, as
well (Supplementary Figure S5A and B).
PCNA SUMOylation site mutants elevate the
accumulation of c-H2AX foci
To validate that SUMOylation of endogenous PCNA has
similar consequences, we over-expressed K164R PCNA,
which can compete against K164 SUMOylation of
endogenous PCNA, in the Rad18/ cell line where the
effect of Rad18-dependent K164 PCNA ubiquitylation
can be ruled out (Supplementary Figure S4D). In line
with the assumption that PCNA-SUMO1 inhibits DSB
formation, expression of K164R PCNA caused a signifi-
cant increase in the number of g-H2AX foci after MMS
treatment (Figure 5D). We also tested the consequences of
the overexpression of the alternative SUMOylation site























   
   
   











































   
   










Figure 4. Effect of SUMO modification of PCNA on homologous
recombination. (A) I-SceI-induced recombinations and (B) spontaneous
recombinations were measured as GFP positive cells after expressing
control FLAG, FLAG-SUMO1, FLAG-PCNA or FLAG-PCNA-
SUMO1. Error bars show standard deviation of the data obtained
from three independent experiments.
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level. Moreover, expression of the KK164, 254RR double
mutant showed some additive effect (Supplementary
Figure S5C and S5D). Taken together that mutations in
SUMOylation sites of PCNA facilitate DSB formation
with the results of overexpression of inhibiting DSB for-
mation by PCNA-SUMO1 fusion suggest a role for
SUMOylation of PCNA in preventing DSB formation.
PCNA-SUMO1 suppresses DNA DSB formation
To examine directly whether PCNA-SUMO1 prevents
DSB formation, we adopted the comet assay under
neutral conditions, which allows the detection of DSBs
at single cell level (37,38). Remarkably, cells expressing
PCNA-SUMO1 exhibited a lower amount of fragmented
double-stranded DNA upon replication-blocking MMS
treatment than did control cell lines expressing PCNA
(Figure 6A). For example, 2 h after MMS treatment
the comet tails were 40% shorter in the presence of
PCNA-SUMO1 fusion than in the control sample
expressing PCNA. Furthermore, kinetic analysis by
measuring the percentage of double-stranded DNA
present in the tail as compared to the intact head DNA
proved that PCNA-SUMO1 expressing cells are less prone
to DSB formation (Figure 6B), which is in accordance
with our data obtained by g-H2AX staining. As can be
expected from these findings, the PCNA-SUMO1 conju-
gate provided enhanced cell survival against treatment
with DNA damaging agents such as MMS and cisplatin
but not against UV suggesting that the rescue mechanisms
could depend on the particular type of DNA damage at
stalled replication forks (Figure 6C and D and
Supplementary Figure S6). Thus, it is possible that UV
lesions are more efficiently bypassed, perhaps due to
Poleta specificity to this damage, than other lesions irre-
spective of the presence of PCNA-SUMO1. Nevertheless,
these data collectively suggest that SUMOylated PCNA
can provide protection against DSB formation, if replica-
tion stalls at an unrepaired lesion.
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Figure 5. SUMO modification of PCNA reduces the accumulation of gH2AX foci. (A) HeLa cells stably expressing FLAG, FLAG-PCNA or
FLAG-PCNA-SUMO1 were fixed 3 h after mock or (B) MMS treatments and stained with anti-FLAG (green), anti-gH2AX (red) and DAPI (blue).
(C) Percentage of cell populations that showed more than two foci for gH2AX at 0.5, 1, 2, 3 and 5 h after MMS treatment was calculated from three
independent experiments; error bars show standard deviations. (D) Effect of the expression of K164R PCNA in RAD18/ HCT116 cells was
revealed by gH2AX staining 3 h after MMS treatment as described above.
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DISCUSSION
Both in vitro and in vivo experiments in this study demon-
strate the SUMOylation of human PCNA with all three
SUMO paralogues, with SUMO1 being predominant. We
revealed that PCNA SUMOylation depends on RFC, sug-
gesting the importance of the presence of PCNA in a
replication ensemble for its SUMOylation to occur.
Remarkably, we observed that cells encountered less
DSBs in the presence of PCNA-SUMO1 fusion protein
as measured by phosphohistone foci and neutral comets.
In line with these data, linear attachment of SUMO1 to
PCNA not only lowered I-SceI-generated DSB-induced
recombination frequencies but also dramatically reduced
spontaneous recombination and conferred damage resist-
ance against replication fork blocking lesions. Although
previous studies have used successfully linear PCNA-
SUMO fusion to obtain insight into the function of
SUMO modification of PCNA, some concern remained
that what degree the PCNA-SUMO1 fusion protein
mirrors the endogenously conjugated PCNA function.
Thus, to provide further evidence for the action of
SUMO modification of PCNA in limiting DSB formation,
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Figure 6. SUMO modification of PCNA limits MMS-induced DNA DSB formation and effects DNA damage sensitivity. (A) Representative images
of HeLa cells stably expressing FLAG, FLAG-PCNA or FLAG-PCNA-SUMO1 either untreated or 2 and 5 h after MMS treatment subjected to
comet assay under neutral conditions. (B) Percentage of comet tail DNA, a measure of DNA DSBs, at 0.5, 1, 2, 3 and 5 h after MMS treatment were
calculated from three independent experiments using three independent stable cell lines; error bars show standard deviations. Significant difference
was detected between the levels of double stand breaks of FLAG FLAG-PCNA-SUMO1, FLAG-PCNA and FLAG-PCNA-SUMO1 expressing cell
lines *P< 0.001). HeLa cells stably expressing FLAG, FLAG-PCNA and FLAG-PCNA-SUMO1 were assayed for cell survival after treatment with
0.005 and 0.01mM MMS (C) or 10 and 150mM Cisplatin (D) as compared to the untreated cells. Error bars show standard deviation from the results
of three independent experiments.
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we overexpressed SUMOylation-site mutant PCNA
proteins, the K164R, K254R and KK164,254RR PCNA
proteins in the Rad18/ cell line that is defective in
Rad18-dependent K164 PCNA ubiquitylation and found
an increase in phosphohistone foci. Thus, impairment
of SUMOylation of human PCNA facilitates DSB forma-
tion as predicted from the results with PCNA-SUMO1
fusion.
For the first time, our results reveal the importance of
the SUMO-PCNA-dependent mechanisms in human
cells, and we show that PCNA SUMOylation-dependent
regulatory functions are not restricted to organisms with a
naturally high rate of recombination such as yeast.
Importantly, this study also provides a previously
unknown role for the SUMO modification of PCNA in
limiting DSB formation, and suggests that in the presence
of SUMO-modified PCNA replication forks encountering
DNA lesions are less likely to be converted to DSBs
(Figure 7). We envision various scenarios for the mechan-
ism by which PCNA-SUMO could prevent DSB forma-
tion, such as providing a higher stability for the replication
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Figure 7. Schematic representation of the suggested multiple roles of SUMOylated PCNA at stalled replication forks. We recommend a novel
function for PCNA-SUMO in preventing DSB formation if replication stalls at DNA lesions (number one in filled circle) or in preventing the
conversion of reversed replication forks to one-ended DSB (number two in filled circle). We also suggest that PCNA-SUMO prevents DSB-induced
recombination and genome rearrangements (number three in filled circle).
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remodelling enzymes or nucleases and promoting damage
bypass by giving access to players of translesion synthesis
or template switch-dependent replication. Moreover, tran-
sient fork reversal could provide an error-free mechanism
for damage bypass whereas stabilized reversed forks could
be accessed by Holliday-junction-specific nucleases
leading to DSB. Therefore, we hypothesize that in the
presence of PCNA-SUMO fork reversal remains transient
and productive (Figure 7). Although these scenarios are
not mutually exclusive, supportive yeast studies have
indicated that PCNA-SUMO can facilitate the Rad6–
Rad18-dependent damage tolerance pathways (19,22).
Further support for our model on human PCNA-
SUMO function is provided by the recent characterization
of human PARI that has been carried out in parallel with
our study (27). PARI exhibits a PCNA-, a Rad51- and a
SUMO-interacting motif, and it binds preferentially to
PCNA-SUMO1 fusion protein over PCNA and
can disrupt Rad51 nucleofilaments. Since PARI also sup-
presses homologous recombination, it was proposed that
PARI resembles yeast Srs2, which is recruited to stalled
fork by PCNA-SUMO and abolishes the access of Rad51
(12,14). While the role of PARI was described in great
detail, no functional assay for the cellular function
of PCNA-SUMO has been carried out. Taken together,
the findings on PARI with our functional assay on
PCNA-SUMO strongly support their functional inter-
action. Human FBH1 and RTEL1 have also been
implicated as functional homologues of yeast Srs2, and
it would be interesting to examine whether these
proteins can also interact with and compete for PCNA-
SUMO, which could provide an additional level of recom-
bination control in human cells.
Better understanding the role of SUMOylation of
human PCNA and its interplay with its interacting
partners can give more insight into how human cells
suppress aberrant recombination events and cancer
development. In summary, our study reveals the import-
ance of SUMO modification of human PCNA in
preventing DSB formation at stalled replication fork and
suggests that PCNA SUMOylation has a more complex
role in safeguarding genome integrity than previously
anticipated.
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